Cancer cells do not merely consume more nutrients than healthy cells; they redesign the systems that process those nutrients to support relentless growth. A new review in Advanced Cancer Research identifies purine metabolism as one of the most important—and potentially most vulnerable—of these remodeled systems. Purines are the molecular building blocks used to make adenine and guanine, the bases required for DNA and RNA. They also form the core of ATP and GTP, which power cellular reactions, and participate in signaling pathways that control proliferation, stress responses and immune activity. By examining how tumors manipulate the full purine metabolic network, researchers from Zhengzhou University describe a strategy in which metabolic enzymes become active drivers of malignancy rather than passive suppliers of cellular fuel.
The review, led by Tang R, Zhu M, Wu Y, Wang S and Song M, maps abnormalities across the three major branches of purine metabolism: de novo synthesis, the salvage pathway and purine catabolism. Under normal conditions, cells balance these routes according to their energy state, nutrient availability and demand for nucleotides. Cancer cells disrupt that balance. They increase the production of purine intermediates when rapid DNA replication requires a constant supply of nucleotides, while also altering recycling and degradation pathways to preserve energy and maintain signaling molecules. This reprogramming can help malignant cells survive oxygen deprivation, nutrient scarcity and treatment-induced stress—conditions that would damage or eliminate many normal cells.
The de novo pathway constructs purine nucleotides from small precursor molecules, including amino acids, bicarbonate and one-carbon units contributed through folate metabolism. Its central steps assemble an activated ribose scaffold into inosine monophosphate, or IMP, which is then converted into adenosine monophosphate and guanosine monophosphate. The review emphasizes that enzymes involved in this process can become metabolic control points in cancer. Phosphoribosyl pyrophosphate synthetase, known as PRPS, generates the activated ribose substrate required to initiate purine construction. When PRPS activity or expression rises, tumor cells may gain an expanded capacity to produce nucleotides. Other enzymes can similarly regulate the balance between nucleotide abundance, redox status and biosynthetic demand, linking the pathway directly to the ability of a cancer cell to divide.
A second important target is inosine monophosphate dehydrogenase, or IMPDH, which controls the conversion of IMP toward guanosine nucleotide production. Guanosine triphosphate is essential for RNA synthesis, protein translation, cytoskeletal organization and signaling through GTP-binding proteins. Increased IMPDH activity has been associated with the high biosynthetic demands of several cancers, making it an attractive pharmacological target. Inhibiting this enzyme can reduce guanine nucleotide availability and potentially slow proliferation, but the therapeutic effect depends on the metabolic flexibility of both tumor and normal tissues. Some cells can compensate by increasing salvage activity or importing nutrients from their surroundings, illustrating why the review presents purine metabolism as an interconnected network rather than a collection of isolated enzymes.
The salvage pathway provides that flexibility by recovering purine bases and nucleosides released during nucleic acid breakdown. Instead of rebuilding purines from the beginning, cells can recycle molecules such as hypoxanthine, guanine and adenine into usable nucleotides. This route is often more energy-efficient than de novo synthesis and may become especially important in tumors exposed to metabolic stress. The balance between synthesis and salvage can differ dramatically from one cancer type to another, or even between neighboring cells within the same tumor. Such heterogeneity may explain why a drug that produces a strong response in one malignancy has limited activity in another. It also raises the possibility that combined treatment could block both new purine production and the recycling mechanisms that allow cancer cells to escape metabolic pressure.
Purine breakdown generates additional signals with consequences beyond nucleotide disposal. Adenosine deaminase, or ADA, is one of the enzymes highlighted in the review because it regulates the levels of adenosine and related metabolites. Adenosine can accumulate in the tumor microenvironment, particularly under conditions of hypoxia, tissue damage and inflammation. By binding to adenosine receptors on immune cells, it can suppress antitumor activity, reduce the function of cytotoxic lymphocytes and promote an immunosuppressive environment. Abnormal purine catabolism may therefore help tumors evade immune surveillance while simultaneously supplying metabolic advantages. The authors argue that enzymes such as ADA should be viewed as multifunctional regulators that connect intracellular metabolism with communication between cancer cells, immune cells and stromal tissue.
This connection between metabolism and the tumor microenvironment is central to the therapeutic promise of the field. A tumor is not a uniform mass of identical cells but a changing ecosystem in which malignant cells compete and cooperate with blood vessels, fibroblasts, immune populations and extracellular matrix. These components exchange metabolites and respond to one another’s demands. A drug that blocks purine synthesis inside cancer cells could cause compensatory changes in surrounding tissue, allowing tumors to obtain nucleosides or alternative nutrients. Conversely, altering extracellular adenosine levels could reshape immune behavior in ways that influence the response to immunotherapy. The review therefore supports the development of purine-targeting drugs in rational combinations, potentially alongside chemotherapy, targeted agents, immune checkpoint inhibitors or treatments that interfere with nutrient transport.
Several compounds that affect purine metabolism already demonstrate the clinical relevance of this strategy. Drugs that inhibit nucleotide synthesis have long been used in cancer treatment, although their activity can be accompanied by toxicity because healthy tissues with rapid turnover also require purines. The next generation of therapies will need to exploit differences between malignant and normal cells, such as oncogene-driven enzyme overexpression, unusual dependence on a salvage route or an inability to adapt when one metabolic branch is blocked. Selective inhibitors directed at PRPS, IMPDH, ADA and other network components could provide greater precision, but the review cautions that enzyme inhibition alone may not be sufficient. Tumors can activate parallel pathways, alter substrate uptake or select resistant populations, making dose, timing and combination design decisive factors.
Future progress will depend on measuring purine metabolism at the level of individual cells and spatially defined tumor regions. Conventional bulk analysis can conceal major differences between cancer cells located near blood vessels, oxygen-poor cores or immune-rich boundaries. Single-cell sequencing may reveal which enzymes are active in distinct malignant and immune populations, while spatial multi-omics can show where metabolic interactions occur within the tumor architecture. Integrating gene expression with metabolite measurements, protein activity and treatment response could identify patients whose tumors are genuinely dependent on a particular purine pathway. Such precision approaches may also help predict toxicity and reveal when metabolic inhibitors should be paired with immunotherapy or other treatments.
The review presents purine metabolism as more than a consequence of rapid cancer growth. It is described as a strategic vulnerability that can influence proliferation, survival, immune suppression and resistance to therapy at the same time. Yet the authors stress that successful translation will require a detailed understanding of metabolic heterogeneity and adaptation. By defining the regulatory networks that control purine production, recycling and degradation, researchers may be able to move beyond broadly toxic antimetabolites toward selective treatments that attack the unique biochemical dependencies of individual tumors. The emerging goal is not simply to deprive cancer cells of nucleotides, but to disrupt the metabolic circuitry that allows them to grow, communicate and withstand treatment.
Subject of Research: Purine metabolism and its role in cancer progression, immune microenvironment remodeling and therapy resistance.
Article Title: Targeting purine metabolism as the next generation of cancer therapeutic strategies
News Publication Date: 14-Aug-2026
Web References: https://doi.org/10.55092/acr20260010
References: Tang R, Zhu M, Wu Y, Wang S, Song M. “Targeting purine metabolism as the next generation of cancer therapeutic strategies.” Advanced Cancer Research, 2026(2):0010. DOI: 10.55092/acr20260010.
Image Credits: Mengqiu Song/Zhengzhou University, China
Keywords: cancer metabolism, purine metabolism, PRPS, IMPDH, ADA, nucleotide synthesis, salvage pathway, purine catabolism, tumor microenvironment, immunotherapy, metabolic reprogramming, cancer therapy resistance
